Using an AAb assay to a panel comprised of the six TAAs, that each of them had elicited a significant higher rate of positive seroreactivity compared to controls (p53, c-myc, HER2, NY-ESO-1, BRCA2, and MUC1), revealed that AAbs to at least one of the six antigens were detected in the sera of 62/97 breast carcinoma patients and 18/40 ductal carcinoma in situ patients [3]. This evidence concerns the gene BRCA2 and ductal breast carcinoma in situ.